Gene Therapy's $250 million acquisition could break through existing CRISPR...

New York-based Emendo Biotherapeutics announced a deal with AnGes to buy the company for $250m.
Emendo is committed to the development of next-generation CRISPR technology for high-precision gene editing of the entire genome.
acquisition will expand AnGes' research and development pipeline for gene editing therapy.
Emendo completed a $61 million round of B financing in January.
CRISPR-Cas9 system, which has been described as the "Surgical Knife of God", has been used in many fields, including medicine, agriculture, basic scientific research, etc.
scientists have also developed a range of CRISPR-Cas9-based tools, such as base editors that convert individual nucleotides to treat genetic diseases caused by single-gene point mutations.
, however, these new technologies are not perfect, and there are problems such as low delivery efficiency, off-target effect and potential security risks.
addition, although CRISPR opens up new gene editing possibilities, the technology is limited by the specificity of nucleases.
OMNI™ technology platform developed by Emendo is a new generation of nuclease discovery platform, but also nuclease optimization platform, a fusion of protein engineering transformation and protein-oriented evolution capabilities.
With the help of a technology platform, the company uses a new type of OMNI™ nuclease to optimize each target gene to meet the three requirements for successful high-precision gene editing: allephase gene specificity, high activity, and no "off-target effect", while maintaining the efficiency of gene editing.
Emendo's technology platform enables more precise gene editing while targeting more previously uneditable targets, with the potential to treat a variety of genetic diseases previously thought to be untreated.
Currently, the company is developing treatment methods for blood diseases and ophthalmological adaptations, with 3 products in the field of blood diseases, targeting severe congenital neutral granulocytic reduction, primary immunodeficiency, bone marrow failure adaptation, and 2 products in the field of ophthalmology for hereditary eye disease.
, Emendo is exploring the technology's use in skin diseases and tumors.
Emendo's research pipeline (Photo: Emendo's official website) this year, with CRISPR gene editing technology won the Nobel Prize in Chemistry, also made the field of gene editing of the field of capital special attention.
November, Metagenomi announced the completion of a $65 million round of A financing to screen out new gene editing systems from microbial macrogenome data, including AI and machine learning; Company has signed a $100 million partnership with Precision BioSciences to work on genome editing, and in November, Spotlight Therapeutics announced the completion of a $30 million round of A financing to develop non-viral gene editing therapy for direct editing of target genes in the body.
: emendoBio Gene Editing Company Acquired by AnGes, Inc. Retrieved Dec 16, 2020, from Takeda's gene editing partner is snapped up for $250M cash as sector continues to heat up. Retrieved Dec 16, 2020, from。